Humanigen, Inc. (HGEN) News

Humanigen, Inc. (HGEN): $6.42

-0.11 (-1.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

Filter HGEN News Items

HGEN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

HGEN News Highlights

  • For HGEN, its 30 day story count is now at 13.
  • Over the past 20 days, the trend for HGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • CMA, FUN and LINK are the most mentioned tickers in articles about HGEN.

Latest HGEN News From Around the Web

Below are the latest news stories about Humanigen Inc that investors may wish to consider to help them evaluate HGEN as an investment opportunity.

Humanigen Stock to $28? This Analyst Thinks So

Shares of Humanigen (HGEN) nose-dived at the start of September after lenzilumab – the company’s prospective treatment for hospitalized Covid-19 patients - was rejected by the FDA. In fact, the negative news drove share losses of 64% during the month, a downturn H.C. Wainwright’s Joseph Pantginis calls “a gross overreaction.” “The agency remains quite engaged and was essentially asking for more data,” says the analyst, who believes that all that has essentially changed is that the potential timing of lenzilumab making its way to patients has been “pushed out.

Marty Shtrubel on TipRanks | October 11, 2021

Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s Potential Positive Economic Value in Hospitalized COVID-19 Patients

BURLINGAME, Calif., October 11, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that a manuscript describing its budget impact model for the treatment of patients hospitalized with COVID-19 is available on medRxiv (link). These results highlight the value of selecting the right treatment for the right hospitalized patients during this time of unprecedented

Yahoo | October 11, 2021

Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe

BURLINGAME, Calif., October 08, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it has entered into an arrangement with Clinigen Group plc ("Clinigen") a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab ("LenzMAP™").

Yahoo | October 8, 2021

Humanigen Announces Participation and Presentation at Multiple Conferences in October

BURLINGAME, Calif., October 05, 2021--Humanigen Announces Participation and Presentation at Multiple Conferences in October

Yahoo | October 5, 2021

Humanigen, Inc.: Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK''s MHRA

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ''cytokine storm'' with its lead drug candidate, lenzilu

FinanzNachrichten | October 1, 2021

Humanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK’s MHRA

BURLINGAME, Calif., October 01, 2021--Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced it has submitted all the planned modules as well as a risk management plan and pediatric investigation plan for the lenzilumab Conditional Marketing Authorization (CMA) in hospitalized COVID-19 patients to the UK’s Medicines and Healthcare Produ

Yahoo | October 1, 2021

Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021

BURLINGAME, Calif., September 29, 2021--Humanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021

Yahoo | September 29, 2021

Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces EMA has appointed rapporteurs as part of process for planned submission of a Marketing Authorization Application for lenzilumab

Business Wire | September 28, 2021

Humanigen, Inc.: Humanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for Lenzilumab

Humanigen plans to submit an MAA under the centralized procedure seeking Conditional Marketing Authorization (CMA) throughout the European Union (EU) for the use of lenzilumab to treat patients ho

FinanzNachrichten | September 28, 2021

Humanigen: Lenzilumab Could Reach the UK Market in 1Q22, Says Analyst

The public markets have generally not been much fun in September but spare a thought for investors of Humanigen (HGEN). Shares have shed 64% of their value over the past month, with most of the losses coming directly after the FDA’s EUA rejection of lenzilumab – Humanigen’s prospective treatment for hospitalized Covid-19 patients. So, what next? Last Wednesday, the company provided an update on its regulatory strategy for lenzilumab, and Oppenheimer’s Kevin DeGeeter has been sifting through the

Yahoo | September 27, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.8307 seconds.